Ulipristal acetate, which is used for treatment of uterine fibroids, is being reviewed because various cases of serious liver problems have been reported in women taking this drug. Following these reports of liver injury and hepatic failure leading to transplantation, The European Medicines Agency (EMA) is advising that Ulipristal acetate should not be initiated in any new patients. EMA has made the following temporary recommendations till the the conclusion of an ongoing EMA safety review: Ulipristal acetate should not be initiated in new patients and no treatment courses should be started in patients who have already completed a previous one.
Liver function tests should be performed at least once a month for all patients taking Ulipristal acetate. If the patient develops transaminase levels more than 2 times the upper limit of normal, treatment should be stopped and patient should be…
